Epigenic Therapeutics to present recent anti-HBV project update at 2024 annual conference of AASLD
Shanghai, China, 26 October 2024- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy for the treatment of prevalent diseases, announced acceptance of an oral presentation at the American Association for the Study of Liver Diseases (AASLD) to be held in San Diego, California, 15-19 November 2024. The presentation is entitled “Robust and sustainable elimination of HBsAg by epigenome modulation enables seroconversion of chronic HBV infection in HBV mouse model”.
The oral presentation will report the preclinical achievements of EPI-003, an anti-HBV clinical development candidate discovered by the company’s proprietary epigenetic modulation technology (EPIREG ®), demonstrating superior pharmacological efficacy in eliminating HBV viral surface antigen (HBsAg) and inhibiting HBV DNA without rebound in preclinical studies compared to other anti-HBV therapies. Moreover, robust and sustainable HBsAg elimination through direct blocking of HBV cccDNA tranion restored the host anti-HBV immune response, offering therapeutic potential for functional or even complete cure for patients with chronic HBV infection.
Publication Number: 107 (Abstract #77)
Session Title: Hepatitis B - Novel Therapeutic Targets and Preclinical Studies
Local Time: 8:15-8:30am, 18 Nov 2024 (PST)
Location: 111 W Harbor Dr, San Diego, CA 92101, USA
Presentation Title: Robust and sustainable elimination of HBsAg by epigenome modulation enables seroconversion of chronic HBV infection in HBV mouse model
About Epigenic Therapeutics
Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene modulation therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene modulation technologies and developing gene modulation therapies, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular, oncology and rare diseases. For more information, visit www.epigenictx.com
Contact
Partnering@epigenictx.com
Media@epigenictx.com
Investors@epigenictx.com
